Irinotecan and raltitrexed: An active combination in advanced colorectal cancer

Annals of Oncology

Volumn 13, Issue 9, 2002, Pages 1424-1429

  Carnaghi, C ^a   Rimassa, L ^a   Garassino, I ^a   Zucali, P A ^a   Masci, G ^a   Fallini, M ^a   Morenghi, E ^a   Santoro, A ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Colorectal cancer; Irinotecan; Metastatic; Phase II trial; Raltitrexed

Indexed keywords

AMINOTRANSFERASE; ATROPINE; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; OXALIPLATIN; RALTITREXED; SEROTONIN 3 ANTAGONIST; SODIUM CHLORIDE;

ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; MALE; MEDICAL ASSESSMENT; METASTASIS; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; PROBABILITY; PROGNOSIS; QUINAZOLINES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; THIOPHENES; TREATMENT OUTCOME;

EID: 0036739135     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf229     Document Type: Article

References (21)

1. Waters J, Cunningham D. The changing face of chemotherapy in colorectal cancer. Br J Cancer 2001; 84: 1-7.
2. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
3. Cunningham D, Pryhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
4. Rougier P, Bugat R, Douillard JY et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-260.
5. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
6. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
7. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993; 53: 5433-5438.
8. Van Kuilenburg AB, Muller EW, Haasjes J et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14 + 1G>A mutation causing DPD deficiency. Clin Cancer Res 2001; 7: 1149-1153.
9. Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother 1994; 28: 374-378.
10. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 1993; 71: 493-509.
11. Cunningham D. Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br J Cancer 1998; 77 (Suppl 2): 15-21.
12. Volk J, Reinke F, van Kuilenburg AB et al. Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer. Ann Oncol 2001; 12: 569-571.
13. Kohne CH, Thuss-Patience P, Friedrich M et al. Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. Br J Cancer 1998; 77: 973-937.
14. Aschele C, Baldo C, Sobrero AF et al. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. Clin Cancer Res 1998; 4: 1323-1330.
15. Ford HE, Cunningham D, Ross PJ et al. Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adeno-carcinoma. Br J Cancer 2000; 83: 146-152.
16. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
17. Hryniuk WM, Figueredo A, Goodyear M. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 1987; 14 (Suppl 4): 3-11.
18. Atkinson EN, Brown BW. Confidence limits for probability of response in multistage phase II clinical trial. Biometrics 1985; 41: 741-744.
19. De Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
20. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky R. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001; 345: 144-146.
21. Rothenberg ML, Meropol NJ, Poplin EA et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19: 3801-3807.